Human MMP9 Assay Kit

Cell-based assay to quantify human MMP9, involved in both normal and pathological tissue remodeling, immunity, and inflammation.

Cisbio's Human MMP9 assay is designed to measure the concentrations of MMP-9 (pro- and active forms) in cell culture supernatants of human origin.

Matrix metalloproteinase (MMP) 9, also known as gelatinase B, is a zinc-dependent endopeptidase secreted as an inactive proenzyme which is then activated by proteolytic cleavage. MMP9 plays a significant role in tissue repair and remodeling by degrading structural components of the extracellular matrix (ECM), such as collagens, gelatin, and elastin. This endopeptidase also has crucial functions in cell growth, migration, inflammation, and angiogenesis by processing a variety of non-ECM molecules such as cytokines and chemokines (e.g. pro-TGF-β, pro-TNF-α, CXCL1, CXCL8, IFN-β).

Its enzymatic activity is regulated by interaction with its physiological inhibitors, the tissue inhibitors of metalloproteinases TIMP1 and TIMP2, that block the access of substrates to the catalytic domain of the enzyme.

MMP-9 is mainly regulated at the level of transcription by several growth factors, cytokines, and bacterial products including LPS.

Upregulation of MMP9, leading to MMP9-TIMP1/2 imbalances, has been linked to tissue fibrosis, cancer, diabetes, arthritis, and cardiovascular diseases. The secretion of this biomarker is therefore a common end point measured when investigating such diseases and to find new drugs.

Assay principle

HTRF® - the homogeneous cell-based sandwich immunoassay

Cisbio's Human MMP9 assay is based on a TR-FRET sandwich immunoassay involving two specific anti-human MMP9 antibodies, one labelled with europium (Eu3+) cryptate (donor) and the other with d2 (acceptor). Both antibodies bind to human MMP9, and the donor-acceptor proximity enables a fluorescent TR-FRET signal. The intensity of the signal is proportional to the concentration of human MMP9 present in the sample.

Assay protocol

Cisbio's Human MMP9 assay can be run in a 96- or 384-well low volume white plate (20 µL final). As described here, cellular samples or standards are dispensed directly into the assay plate for the detection of human MMP9 by HTRF® reagents. The antibodies labelled with HTRF fluorophores may be pre-mixed and added in a single dispensing step. No washing steps are needed. The protocol can be further miniaturized or upscaled by simply resizing each addition volume proportionally.

The assay can be performed on frozen or freshly prepared cellular samples, and the HTRF signal can be recorded with most TR-FRET multimode plate readers.

Product specifications

Final assay volume 20 µL
Sample size 16 µL
Kit components Frozen standard, frozen detection antibodies, buffers & protocol
LOD* (Mean Std 0 + 2 SD) 0.21 ng/mL
Assay range (LOQ* to Std max) 1.05 - 200 ng/mL
Time to result Overnight at RT
Species reactivity Human
Specificity - Measures pro- and active forms of human MMP9
- Measures free MMP9 and MMP9 bound to TIMP1 or TIMP2
- No cross-reactivity with human MMP1 or human MMP2

 

It is mandatory to prepare cell supernatants and to dilute human MMP9 standard with a culture medium supplemented with serum (2 to 10%) or BSA (0.2 to 1%), to avoid MMP9 sticking to culture vessels and assay plates.

*LOD and LOQ obtained in diluent on the PHERAstar FS reader (BMG Labtech). These values may vary from one HTRF reader to another.

Product performances

MMP-9 upregulation induced by LPS and PMA in the human hepatic stellate cell line LX-2*

The human hepatic stellate cell line LX-2* was plated in a 96-well plate (50,000 cells/well) in complete culture medium. The day after, cells were treated for 24h with 100 µL of increasing doses of LPS or PMA in FBS-free medium supplemented with 0.2% BSA. Cell supernatants were collected for the quantitative measurement of secreted MMP9 levels.

*Provided by EMD Millipore (product number #SCC064)

In accordance with data from the literature, LPS treatment leads to a dose-dependent increase in the secretion of human MMP9.

Cell treatment with PMA for 24h induces an upregulation of the secreted level of human MMP9.

MMP-9 upregulation induced by PMA and ROS in the human breast cancer cell line MCF-7

The human breast cancer cell line MCF-7 was plated in a 96-well plate (25,000 or 200,000 cells/well) in complete culture medium. The day after, cells were treated for 24h with 50 µL of increasing doses of PMA or H2O2 diluted in FBS-free medium supplemented with 0.5% BSA. Cell supernatants were collected for the quantitative measurement of secreted MMP9 levels.

As expected, cell exposure to PMA or H2O2 for 24h leads to a dose-dependent increase in the secretion of human MMP9.

Correlation between HTRF Human MMP9 assay kit and a commercial ELISA

A side-by-side comparison between HTRF Human MMP9 assay kit and a commercial ELISA was performed on cell supernatants of LX-2* cells treated with PMA for 24h (in FBS-free medium + 0.2% BSA).

The two methods are very well correlated, as demonstrated by the value of the correlation coefficient (r) which was close to 1.

*Provided by EMD Millipore (product number #SCC064)

Part#, inserts & MSDS

Ordering Info

DescriptionCat. noProduct insertMSDS
Human MMP9 kit - 500 tests62MM9PEG
-
Human MMP9 kit - 10,000 tests62MM9PEH
-
Human MMP9 kit - 100,000 tests62MM9PEJ
-
-

Companion products

DescriptionCat. noProduct insertMSDS
Human MMP9 kit - Standard62MM9CDA
-
-

ドキュメント